Patient Profiling for Treatment Toxicity: Potential Use of Clinical and Genomic Factors |
| |
Authors: | Terri S Armstrong Mark R Gilbert |
| |
Institution: | University of Texas Health Science Center-Houston School of Nursing, 6901 Bertner, Room 791, Houston, TX 77030, USA. Terri.S.Armstrong@uth.tmc.edu |
| |
Abstract: | Significant advances have been made in the identification of genes associated with the occurrence and prognosis of a variety
of cancers. Recent efforts have also identified specific genomic single nucleotide polymorphisms (SNPs) that are associated
with treatment toxicity in oncology, including toxicity associated with irinotecan, 5-FU, and 6-mercaptopurine. Despite the
identification of these potential genomic predictors, their clinical use has been limited. Recent work has identified combined
clinical characteristics and SNPs associated with toxicity with temozolomide. This combined approach may allow for identification
of those at risk, and by using clinical parameters for screening, further refine those who require the more expensive genomic
testing. This approach, as well as evaluation of clinical utility, economic impact, and ease of use are important components
necessary for evaluation and use of genomic predictors of toxicity in the future. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|